SOURCES SOUGHT
A -- INNER CITY ASTHMA CONSORTIUM
- Notice Date
- 9/2/2008
- Notice Type
- Sources Sought
- NAICS
- 541712
— Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Office of Acquisitions, 6700 B Rockledge Room 3214 MSC7612, Bethesda, Maryland, 20892-7612
- ZIP Code
- 20892-7612
- Solicitation Number
- NIHAI2008044_Sources-Sought
- Archive Date
- 10/9/2008
- Point of Contact
- Andrea Giuliano, Phone: 301-496-0612, Robert Koplos,, Phone: 301-451-7457
- E-Mail Address
-
giulianoan@niaid.nih.gov, koplosro@niaid.nih.gov
- Small Business Set-Aside
- N/A
- Description
- Research supported and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), strives to better understand, treat, and ultimately prevent immunologic, infectious, and allergic diseases. The NIAID Division of Allergy, Immunology, and Transplantation (DAIT) supports extramural basic, pre-clinical and clinical research focusing on immune-mediated diseases through a variety of research grants and contracts. Over the past two decades, attention has been focused on the disproportionate burden of asthma on minority populations, particularly African-American and Hispanic residents of U.S. inner cities. Since 1991, DAIT NIAID has supported research programs to develop effective behavioral, educational and environmental interventions to reduce asthma severity among inner city children. The NIAID Inner City Asthma Consortium was established in FY2002 under a contract to the University of Wisconsin-Madison. The current NIAID Inner City Asthma Consortium is composed of an administrative center and ten clinical sites. A separate contract to establish and operate a Statistical and Clinical Coordinating Center to support the clinical research program of the Consortium is in place. Ongoing and completed studies have focused on the standardization of cockroach allergens and on biomarker evaluation to guide asthma treatment. Ongoing studies include a prospective, longitudinal evaluation of environmental factors that influence the development of the immune system and asthma and Phase I and Phase II clinical trials of immunotherapeutic modalities. The Inner City Asthma Consortium will expand its focus on the immunopathogenesis of asthma in inner city populations through the addition of Basic Science Sites. The overall objectives of the Inner City Asthma Consortium are to: 1.Design and conduct clinical studies with the goals of a) improving asthma control, b) preventing the development of asthma in children residing in the inner cities of the United States using primarily immune system-targeting interventions, and c) improving asthma phenotyping using validated biomarkers. 2.Design and conduct longitudinal birth cohort studies with the goals of a) providing novel information on the early immunopathogenesis of asthma, b) identifying risk factors for the development of asthma in children residing in the inner cities of the United States, c) understanding differences in the early immunopathogenesis of asthma between inner city and non-inner city children, and d) developing studies to prevent the development of asthma. 3. Design and conduct mechanistic studies involving human subjects with the goal of elucidating the immunopathogenesis of asthma in the inner city environment. 4. Develop, validate and implement basic science methodology to support the studies conducted under objectives 1, 2 and 3 listed above. It is anticipated that one cost reimbursement completion type contract will be awarded for a period of five (5) years, beginning approximately September 2009, with an anticipated annual total effort of approximately 67.8 FTEs for the base period. Potential sources must demonstrate and document their ability to perform the following in their capability statements: The Contractor shall a) establish and maintain eight (8) Clinical Study Sites to recruit children and adult subjects primarily among U.S. inner city populations and conduct clinical studies with subjects recruited from these populations; b) establish and maintain two (2) Basic Science Sites to design studies involving human subjects to test mechanistic hypotheses on the immunopathogenesis of asthma in the inner city populations, to develop, validate and implement basic science methodology to support the primary outcomes of these mechanistic studies, and to serve as core laboratories for the measurement of laboratory outcomes or train and assist technical personnel at the clinical study sites to perform these measurements; c) design and execute clinical trials and cross-sectional clinical studies to improve asthma control, prevent the development of asthma in children residing in the inner cities of the U.S., using primarily immune system-targeting interventions, and improve asthma phenotyping using validated biomarkers; d) continue, for an additional five (5) years, the Urban Environment and Childhood Asthma (URECA) longitudinal birth cohort study that was designed and initiated under the current Consortium contract; e) design and execute other longitudinal birth cohort studies to provide novel information on the early immunopathogenesis of asthma, identify risk factors for the development of asthma in children residing in the inner cities of the U.S., enhance our understanding of the differences in the early immunopathogenesis of asthma between inner city and non-inner city children, and lead to new studies to prevent the development of asthma; f) design and execute mechanistic studies involving human subjects with the goal of elucidating the immunopathogenesis of asthma in the inner city environment; g) develop, validate and implement basic science methodology to support all clinical studies; h) coordinate and collaborate with the Consortium Statistical and Clinical Coordinating Center in providing a broad range of clinical research support services, including development of protocol-related materials, data collection, management and quality control, and the analysis of final study data. Capability statements submitted as a result of this announcement should demonstrate the offerors’ qualifications and experience, specifically providing evidence as to their capability to perform this requirement, with particular attention to the following:
- Web Link
-
FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=bf28ea566b19d2a7c28f069f3bb7afa4&tab=core&_cview=1)
- Place of Performance
- Address: Place of performance is unknown at this time, United States
- Record
- SN01656718-W 20080904/080902220221-bf28ea566b19d2a7c28f069f3bb7afa4 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |